(Reuters) – The U.S. Food and Drug Administration on Monday approved Shire Plc's lifitegrast eye drops for treating signs and symptoms of dry eye disease, allowing the company to bring to market its most important pipeline medicine. Lifitegrast, which will be marketed as Xiidra in the United States, is expected to launch in the third quarter. It treats an eye disease that affects nearly 16 million adults in the United States.
Originally posted here:
FDA approves Shire’s keenly-watched eye drug
